Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: analysis of the NIVOREN GETUG-AFU 26 study

Immune checkpoint inhibitors are standard of care in metastatic renal cell carcinoma but their activity and safety in elderly patients is insufficiently explored. We evaluated outcomes of elderly patients with mRCC treated with nivolumab in the GETUG-AFU 26 NIVOREN phase 2 trial (NCT03013335) and conducted exploratory circulating biomarker analyses.

Source: European Journal of Cancer - February 2, 2024 Category: Cancer & Oncology Authors: Lo ïc Mourey, Larissa Tames Rainho, Cécile Dalban, Lucía Carril-Ajuria, Sylvie Negrier, Christine Chevreau, Gwenaëlle Gravis, Constance Thibault, Brigitte Laguerre, Philippe Barthelemy, Delphine Borchiellini, Marine Gross-Goupil, Lionnel Geoffrois, Tags: Original Research Source Type: research